Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 32.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 442,579 shares of the biopharmaceutical company’s stock after purchasing an additional 107,566 shares during the quarter. Teacher Retirement System of Texas’ holdings in Gilead Sciences were worth $40,881,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FMR LLC increased its stake in Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP increased its stake in Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares during the last quarter. Pacer Advisors Inc. increased its stake in Gilead Sciences by 723.3% during the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after acquiring an additional 5,653,075 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Gilead Sciences during the fourth quarter worth $207,340,000. Finally, Point72 Asset Management L.P. increased its stake in Gilead Sciences by 350.1% during the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after acquiring an additional 1,793,145 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several recent analyst reports. Piper Sandler raised their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Royal Bank of Canada lifted their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company lifted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $104.52.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have sold 302,785 shares of company stock worth $30,503,250. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Down 1.5 %

Shares of NASDAQ GILD opened at $105.87 on Friday. The company has a market capitalization of $131.84 billion, a price-to-earnings ratio of 286.14, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business has a 50-day moving average of $103.33 and a two-hundred day moving average of $93.56. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.